Treatment for bleeding from esophageal varices
Life-2023-02 Study on the Efficacy of Growth Inhibitors After Endoscopic Treatment of Acute Esophagogastric Variceal Bleeding
This study is testing if giving growth inhibitors to patients who have had bleeding from esophageal varices can help them recover better after treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 33 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University Academic / other |
| Locations | 1 site (Hanzhou, Zhejiang) |
| Trial ID | NCT06011980 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of growth inhibitors in patients who have experienced acute esophagogastric variceal bleeding. Participants will be selected based on their stable condition and will undergo a CTP test to assess portal vein blood flow before receiving endoscopic treatment. Following this, they will be randomly assigned to either receive growth inhibitors for five days or not receive any post-treatment intervention. The goal is to determine if the growth inhibitors can improve outcomes after the endoscopic procedure.
Who should consider this trial
Good fit: Ideal candidates are patients with acute esophagogastric variceal bleeding who are stable and have hepatic cirrhosis.
Not a fit: Patients with previous treatment for acute esophagogastric bleeding, those in the ICU, pregnant individuals, or those with immune deficiencies may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly reduce complications and improve recovery for patients suffering from acute esophagogastric variceal bleeding.
How similar studies have performed: While this approach is being tested in this specific context, similar studies on growth inhibitors have shown promise in other settings, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * acute esophagogastric bleeding with hepatic cirhosis; * stable status (no active bleeding) Exclusion Criteria: * endoscopic test limitation; * previous acute esophagogastric bleeding treatment history; * ICU; * pregnant; * Immunity disabled;
Where this trial is running
Hanzhou, Zhejiang
- 2nd Affiliated Hospital, School of Medicine, Zhejiang University — Hanzhou, Zhejiang, China (Recruiting)
Study contacts
- Study coordinator: Wei Wei
- Email: wwze@zju.edu.cn
- Phone: 15267175186
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.